RBC Life Sciences Granted Marketing Rights toStem-Kine™ Supplement

On July 8, 2011 · In Stem Kine

RBC LifeSciences
For immediate Release
May 18, 2011

RBC Life Sciences Granted Marketing Rights toStem-Kine™ Supplement

Irving, Texas (RBC Life Sciences: OTCBB: RBCL) – RBC Life Sciences, Inc.announced that it hasbeen granted a license to market Stem-Kine in North America and 36 other countries. Stem-Kine is a dietary supplementthat nourishes a person’s bone marrow enabling it to increase theproduction of circulating adult stem cells.

Stem-Kine was developed by Dr. Neil Riordanbased on a study of bone marrow metabolism and the production of adult stemcells. It is a combination of well-known natural nutrients made with aproprietary fermentation process.

In collaboration with a group of scientists inmajor universities and research organizations, a human clinical pilot study wasconducted that showed a 100% increase in stem cell levels over a two-weekperiod, as reported in a peer-reviewed medical journal.

Subsequently an 18-patient study was conductedthat showed a 53% increase in CD34 type stem cells, and a 90% increase in CD133type stem cells, both over a two-week period. This second study was alsoreported in a peer-reviewed medical journal, with the comment by the authors,To our knowledge this is the first study demonstrating profound mobilizationeffect with possible clinical significance by a food supplement-based approach.

 

RBC Life Sciences, Inc. is a 20-year-old publiccompany based in Irving, Texas that markets a broad line of highquality nutritional products through its dietary supplement division, RBC Life.

The statements above, other than statements of historical fact,may be forward-looking. Actual events will be dependent upon a number offactors and risks including, but not limited to, changes in plans by theCompany’s management, delays or problems in production, changes inthe regulatory process, changes in market trends, and a number of other factorsand risks described from time to time in the Company’sfilings with the Securities and Exchange Commission.

 

Comments are closed.